A healthcare company headquartered in the US with multiple offices globally has expanded to multiple subsidiaries that focus on different indications of unmet need. The firm is currently seeking promising assets to license and acquire, to supplement their existing asset portfolio and continue to expand to new disease areas. The firm is open to global opportunities.
The firm is only interested in therapeutics opportunities and is generally open to all indications and modalities. The firm has a preference for clinical stage assets, but may consider pre-clinical assets on occasion.
The firm has no specific company or management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based Healthcare Company Seeks to In-License and Acquire Clinical Therapeutic Assets to Create New Subsidiaries
30 Jun- Comments Leave a Comment
- Categories Hot Mandates
Popular Topics
Listen to the Podcast
Top Posts
- Congratulations to the IPC Winners, Next Up RESI Boston, June 5-7
- Companies to Watch in 2022
- Strategic LPs: A New Approach In Corporate Health Innovation
- Drug Development: What Does It Cost, and Who Has The Capital?
- The Art of Raising Money for a Life Sciences Company
- RESI on MaRS Innovation Challenge – Winners Announced
- Advice from Oncology Investors: How to Differentiate Your Startup in the Cancer Space
- In Partnership with KOTRA: Uncovering the Korean Biotech Start-Up Scene at RESI Boston
- Innovator's Pitch Challenge Judges at Digital RESI March
- Meet The Family Offices that Invest Directly in Biotech, Medtech and Healthcare IT Startups
Recent Posts
- Congratulations to the IPC Winners, Next Up RESI Boston, June 5-7
- Digital RESI March – A Tailor Made Conference for Early-Stage Life Science Fundraising Startups
- Audience Access Pass – A Runway for Your Fundraising Journey
- Innovator’s Pitch Challenge Judges at Digital RESI March
- Hot Investor Mandate: Multi-Billion AUM Investment Firm Seeks to Invest in All Areas of Life Sciences & Healthcare Across the Globe
Hot Mandates
-
Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
-
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
-
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
-
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
-
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
LSN Twitter
- RT @UMassM2D2: In two week,s @LSciNation is awarding a 2-day virtual registration to the upcoming RESI Boston to one #Startup in the Cycle… 17 hours ago
- Tech Hub Monthly! A newsletter for tech hub staff who are looking to increase #fundraising and marketing efforts fo… twitter.com/i/web/status/1… 20 hours ago
- Congratulations to the three Innovator's Pitch Challenge (IPC) winners - SiVEC Biotechnologies, Reglagene &… twitter.com/i/web/status/1… 1 day ago
- Congratulations to Digital RESI March IPC Winners – SiVEC Biotechnologies, Reglagene & @AmpSciences! Now accepting… twitter.com/i/web/status/1… 2 days ago
- RESI is coming back to Boston this June as a hybrid format with a one-day (June 5) in-person conference experience… twitter.com/i/web/status/1… 4 days ago
- RT @ditcaldwell: Enjoyed pitching alongside @theradaptive and @kortuc_inc in the Digital #RESI #Innovators Pitch Challenge yesterday. #star… 1 week ago
Leave a Reply